×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Bakersfield.com
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC. Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET (Euronext...
15 hours ago
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
GlobeNewswire
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET (Euronext...
15 hours ago
Oxurion to file for bankruptcy following trial failure
Clinical Trials Arena
Oxurion's diabetic macular oedema drug, THR-149, failed to meet its primary endpoint in the Phase IIb trial.
5 months ago
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
Yahoo Finance AU
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV...
1 week ago
Oxurion plans bankruptcy filing as phase 2 eye disease failure evaporates remaining optimism
Fierce Biotech
Oxurion plans bankruptcy filing as phase 2 eye disease failure evaporates remaining optimism ... Oxurion's vision was just a mirage. The last...
5 months ago
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC | GlobeNewswire by notified
NTB Kommunikasjon
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext...
3 weeks ago
Oxurion unlocks $1m from Atlas for diabetic macular oedema therapy
Pharmaceutical Technology
Oxurion has received €1m ($1.09m) in funding from Atlas as part of a subscription agreement with Atlas totalling up to €20.8m ($25m).
9 months ago
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LL
StreetInsider.com
Regulated Information. Leuven, BELGIUM, Boston, MA, US – July 26, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a...
9 months ago
Oxurion reaches enrollment target in clinical trial for THR-149 in DME
Ophthalmology Times
According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for...
11 months ago
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with ...
GlobeNewswire
Oxurion shall immediately partly reimburse the debt transferred from Kreos/Pontifax to Atlas with its own financial means and funds provided via...
4 months ago